UnknownPHASE1, PHASE2NCT05639179

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Principal Investigator
Wang Sanbin, Doctor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Intervention
UCAR-T Cells(biological)
Enrollment
30 enrolled
Eligibility
2-75 years · All sexes
Timeline
20222025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05639179 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials